ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on improving vision after cataract surgery, has announced select preliminary financial results for the second quarter of 2026 and provided updates to its standalone product pipeline. This follows the announcement on July 6 about the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable presbyopia-correcting intraocular lenses. Total company revenue for the second quarter of 2026 is expected to be approximately $32 million to $34 million, which includes $5 million to $7 million in revenue recognized from the RxSight Alcon strategic collaboration, with the specific amount expected to be reported in August with the company’s financial results for the second quarter of 2026.